Biomanufacturing
is under increasing pressure
New biomedicines are more and more complex
Bispecific/Trispecific/… antibodies, cell & gene therapy…
The wave of biomedicines is on its way to the top:
- Biologics are predicted to overtake small molecules in sales by 2027
- 22.000+ biomedicines are currently in the pipelines
Leading to massive investment needs
To build new facilities, and modernize existing ones
While profitability requirements have never been higher
Given the funding challenges for pharma and biotech companies
And pressure for speed to market is a constant constraint
Race against time for each new biomedicine, to maximize the exploitation period of patent-protected drugs
Adopting C3P3® technology
is a simple answer to these biomanufacturing issues
Combine profitability with your quest for a healthier and greener world:
More biomedicines
Hard-to-express biomedicines
Faster drug development
Less equipment and reagent consumption
Revolutionize
Revolutionize your biomanufacturing with Eukarÿs’ cutting-edge C3P3® technology, delivering unprecedented yield increases:
x5 in CHO cells and x7 in HEK-293 cells
Compared protein production yield

Reduce your operational costs
Save time in your drug development
Release pressure coming from factory saturation: rely on fewer batches thanks to higher yields. Just one week of delay can save at least $20M on a blockbuster drug.
Reduce your investments in new equipments
With Eukarÿs, smaller equipments are required for a similar amount of biomedicines production
Reduce the number of production units you need to build and certify
Fewer manufacturing units for the same amount of biomedicines production
Increase your ability to produce hard-to-express biomedicines
25% of drug candidates are discontinued at the research stage due only to production issues
Seamless integration
of C3P3® into your bioproduction workflow

Keep your equipment and maintain your process
C3P3® works alongside your current technologies without requiring new investment, complementing your biomanufacturing processes with minimal change and no disruption to your workflow. C3P3® comes on top, so you can use it within your own process, regardless of your other upstream or downstream technologies.

Use the same technology for all your batches
Universal: from simple or complex antibodies to recombinant proteins, viral vectors, and VLP, C3P3® is plug and play for all biomedicines, while maintaining quality and preserving glycosylation and folding. It can synthesise and mature mRNA-of-interest starting from any gene-of-interest, ensuring a swift and seamless adaptation of any gene(s)-of-interest to the C3P3® platform.

Maximize your production yields
With proven results – yield increases of up to x5 in CHO and x7 in HEK-293 – you will see immediate improvements in biomedicines production from discovery to industrial scale.
Deploy C3P3® technology in your stable or transient expression systems:
- Stable expression: engineer your cells to make them hyper-productive
- Transient expression: co-transfect our C3P3® plasmid together with your ones
Want to try our technology?
Step 1:
An exploratory call to understand your needs.
Step 2:
Validate the technology with a proof of concept on the molecules of your choice.
Step 3:
Full deployment across your biomedicines, ensuring higher yields and lower costs.
Trusted by:
